Ovarian Cancer

P3, N=1407, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2028 --> Dec 2026

Our findings emphasize that when imaging or cytology suggests multiorigin components, clinicians should pursue thorough intraoperative exploration, multisite biopsies, and prophylactic appendectomy. Ultimately, the management of such patients requires highly individualized surgical and chemotherapeutic strategies that account for the divergent biological behaviors and therapeutic sensitivities of both HGSOC and well-differentiated appendiceal mucinous adenocarcinoma to optimize oncological outcomes.

P=N/A, N=250, Recruiting, University of Colorado, Boulder

A 40-year-old woman with FIGO stage IVB, BRCA-wildtype HGSOC developed rapid multi-drug resistance following neoadjuvant chemotherapy, optimal cytoreduction, and progression on maintenance olaparib/bevacizumab, gemcitabine, and a USP1 inhibitor. By utilizing topoisomerase I inhibitors, agents like YL205 bypass microtubule-stabilization resistance induced by prior taxane exposure, while "bystander effects" address intratumoral heterogeneity. Longitudinal, biomarker-matched strategies and proactive toxicity management are essential to achieving deep tissue clearance in heavily pretreated HGSOC.

Radiomics, which involves extracting high-dimensional features from medical images, has shown promise in differentiating between benign and malignant tumors, predicting genetic mutations (e.g., BRCA), and assessing tumor heterogeneity. Artificial intelligence (AI) models, particularly deep learning (DL) algorithms, have demonstrated high accuracy in diagnosing OC and predicting patient outcomes, often outperforming traditional methods.

Finally, we propose a biomarker-guided framework that links antigen-presentation competence, immune engagement, dominant suppressive axes, and ascites-specific biology to rational therapeutic matching. This mechanism-centered view supports more precise trial design and provides a roadmap for combination immunotherapy in advanced ovarian cancer.

Complete remission was obtained using stereotactic radiotherapy to the brain lesions, followed by platinum-based chemotherapy and maintenance therapy with bevacizumab and olaparib...Their role in this setting remains emerging and primarily supported by limited case reports and small series. Further studies are required to better define their role.

In silico knockout of NAP1L1 in epithelial cells indicated the perturbation of focal adhesion and cell-substrate junction pathways and high expression of prometastatic genes, including Jun proto-oncogene, AP-1 transcription factor subunit, JunB proto-oncogene, AP-1 transcription factor subunit, and activating transcription factor 3. Our study deciphered the immune and epithelial cell dynamics of metastasis and identified NAP1L1 as a novel regulator of epithelial cell reprogramming and metastatic progression.

Animal experiment further confirmed that downregulating THUMPD3-AS1 enhanced olaparib sensitivity to hinder the in vivo growth of OC cells through inhibiting PI3K/AKT/mTOR pathway. Our research revealed THUMPD3-AS1 as a promising target for OC therapy.

Ligand-based similarity screening against the COCONUT database followed by molecular docking and MD simulation identified three promising compounds (662142, 733302, and 883576) with improved binding affinity and conserved interactions with Topoisomerase-1. This integrative framework highlights the potential of combining machine learning, pharmacogenomics, and molecular modelling for biomarker discovery and drug prioritization in ovarian cancer.

Clinically, high CHP1/TMEM87A expression exhibited stage-dependent prognostic significance (favorable in early-stage, unfavorable in late-stage HGSC), as assessed by Kaplan-Meier survival analysis of publicly available datasets. These findings suggest that the CHP1-TMEM87A complex may serve as a mechanosensitive regulator of HGSC metastasis and propose gluconate-based targeting as a promising therapeutic strategy.